A one-unit increase in cholangioscopy procedures was linked to a 24% increase in subsequent cholangiocarcinoma diagnoses the ...

In an interview, Arvind Bussetty, MD, and Arvind Trindade, MD, delved into the rising rates of gastrointestinal cancers among younger patients.

A pooled analysis of over 2.4 million adults across four continents shows a modest but significant increase in pancreatic ...

in frontline metastatic pancreatic ductal adenocarcinoma Plans for registrational Phase 3 study underway in frontline metastatic pancreatic ductal adenocarcinoma Company will host an R&D investor ...

Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study). JCO 0 , JCO-24-01378 DOI: ...

ABSTRACT: Pancreatic cancer, a highly lethal digestive tract malignancy, has a 5-year survival rate below 10%, primarily due to late-stage diagnosis and limited therapeutic options. Over 80% of ...

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer. The more common BRCA wild-type (wt) subtype is particularly resistant to standard treatments such as gemcitabine and ...

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer, with tumor cells readily disseminating to other organs through the bloodstream, lymphatic system, and nervous system, thereby ...

Objective Pancreatic ductal adenocarcinoma (PDAC) is a disease of unmet medical need. While immunotherapy with chimeric antigen receptor T (CAR-T) cells has shown much promise in haematological ...